A New Report on Pain in America: Like Déjà Vu All Over Again
December 2nd 2011The report notes that pain is a significant public health problem that affects more than 100 million Americans, costs our society at least $560 to $659 billion annually, and can be severely detrimental to the lives of sufferers.
Topical NSAIDs: Old Wine in a New Bottle
October 1st 2008Over the past decade, NSAIDs have been on a roller-coaster ride almost as wild as that now being experienced by this country’s housing and financial markets. The selective COX-2 inhibitors-first celecoxib (Celebrex) and then rofecoxib (Vioxx) and valdecoxib (Bextra)-promised to revolutionize the treatment of pain.
Update on Treatment of Low Back Pain: Part 2
July 2nd 2008The guideline divides the therapies it reviewed into nonpharmacological, nonsurgical, and pharmacological categories. The nonpharmacological category includes a wide range of modalities from treatments that patients can perform themselves, such as yoga and exercise, to psychotherapy, acupuncture, and a variety of physical therapy techniques, including heat and laser treatments.
Evaluation and Management of Low Back Pain: Part 1
May 2nd 2008Patients with low back pain (LBP) face many decisions, ranging from the nature and extent of the evaluation they should undergo to determining which treatments are likely to be most effective. These choices can be confusing not only to those who are in pain but also to their health care providers.
NSAIDs and Cardiovascular Disease
June 1st 2007NSAIDs have long been considered first-line treatments for a variety of pain conditions--most notably, musculoskeletal pain. Many NSAIDs are available in over-the-counter preparations, so they are inexpensive and, for better or worse, can be obtained without consulting physicians or health care professionals. For most patients, these drugs were considered safe, except in those who are at risk for GI bleeding or who have renal dysfunction. The most common adverse effect associated with NSAID use is GI distress.